Latest Articles

Publication Date
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Medroxyprogesterone Acetate Market Forecast 2026-2035: Growth Driven by Contraceptive Access and Hormone Therapy - News and Statistics - IndexBox

Medroxyprogesterone Acetate Market Forecast 2026-2035: Growth Driven by Contraceptive Access and Hormone Therapy - News and Statistics IndexBox

Published: July 10, 2026, 11:11 a.m.
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy - BiotechDispatch

Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy BiotechDispatch

Published: July 2, 2026, 12:04 a.m.
Cartherics emerges as Asia Pacific leader in off the shelf immune cell therapy - PharmaDispatch

Cartherics emerges as Asia Pacific leader in off the shelf immune cell therapy PharmaDispatch

Published: July 1, 2026, 1:09 a.m.
Surgery or Hormonal Therapy for Rectovaginal Endometriosis? - Medscape

Surgery or Hormonal Therapy for Rectovaginal Endometriosis? Medscape

Published: June 30, 2026, noon
Does Surgery Outperform Hormonal Therapy for Rectovaginal Endometriosis? - Medscape

Does Surgery Outperform Hormonal Therapy for Rectovaginal Endometriosis? Medscape

Published: June 30, 2026, noon
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy - MSN

Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy MSN

Published: June 27, 2026, 6:48 p.m.
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy - Clinical Trials Arena

Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy Clinical Trials Arena

Published: June 26, 2026, 4:52 p.m.
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy - Pharmaceutical Technology

Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy Pharmaceutical Technology

Published: June 26, 2026, 10:33 a.m.
Fertility-Preserving Therapy May Impair Endometrial Function and IVF Success After Endometrial Cancer:... - Medical Dialogues

Fertility-Preserving Therapy May Impair Endometrial Function and IVF Success After Endometrial Cancer:... Medical Dialogues

Published: June 19, 2026, 2:30 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!